National Yang Ming Chiao Tung University
National Yang Ming Chiao Tung University
31/07/2024 | Press release | Distributed by Public on 31/07/2024 14:04
NYCU and TSH Biopharm Launch Industry Academia Co Creation to Foster Next Generation Pharmaceutical Talents and Develop Precision Medicines
Translated by Hsuchuan
Edited by Chance Lai
______
Edited by Chance Lai
______
National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm officially signed a five-year industry-academia collaboration memorandum of understanding (MOU) on July 22. The collaboration includes the joint establishment of career mentorship courses and the promotion of biotechnology and pharmaceutical research. The aim is to enhance academic exchange, promote co-creation between industry and academia, and foster talent development. This collaboration marks a shared commitment to innovation in cross-disciplinary learning and research, laying a solid foundation for future development with a focus on medicine.
Utilizing AI Technology to Focus on the Development of Vascular Disease and Anti-Aging Drugs
Chairman of TSH Biopharm, Chuan Lin, stated that while research and development in the biomedical industry is time-consuming, the product lifecycle is also relatively long. Therefore, nurturing outstanding talent is one of the key factors in driving industry innovation. By combining NYCU's rich research background and AI precision medicine development technology with TSH Biopharm's commercialization capabilities, we hope to jointly contribute to the health and well-being of an aging society and set a new benchmark for medical industry-academia collaboration in Taiwan.
TSH Biopharm has been deeply engaged in the field of cardiovascular disease for many years and has developed excellent domestically produced new drugs in the areas of gastroenterology, ophthalmology, and central nervous system medications. The company is rooted in the Taiwan market with niche pharmaceuticals while actively expanding overseas.
NYCU combines strengths in biomedical sciences and electronic communications, holding numerous patents in biotechnology and drug development. The university also conducts extensive research in chronic diseases such as cardiovascular diseases, diabetes, and kidney diseases.
The signing of this MOU integrates the strengths of both parties, enhancing collaboration in biotechnology and drug development, with a particular focus on vascular disease, organ protection, and anti-aging. Through early validation of new functions for specific targets, patent applications, and AI drug screening, both parties are committed to addressing unmet clinical needs and improving the efficiency of new drug development.
Utilizing AI Technology to Focus on the Development of Vascular Disease and Anti-Aging Drugs
Chairman of TSH Biopharm, Chuan Lin, stated that while research and development in the biomedical industry is time-consuming, the product lifecycle is also relatively long. Therefore, nurturing outstanding talent is one of the key factors in driving industry innovation. By combining NYCU's rich research background and AI precision medicine development technology with TSH Biopharm's commercialization capabilities, we hope to jointly contribute to the health and well-being of an aging society and set a new benchmark for medical industry-academia collaboration in Taiwan.
TSH Biopharm has been deeply engaged in the field of cardiovascular disease for many years and has developed excellent domestically produced new drugs in the areas of gastroenterology, ophthalmology, and central nervous system medications. The company is rooted in the Taiwan market with niche pharmaceuticals while actively expanding overseas.
NYCU combines strengths in biomedical sciences and electronic communications, holding numerous patents in biotechnology and drug development. The university also conducts extensive research in chronic diseases such as cardiovascular diseases, diabetes, and kidney diseases.
The signing of this MOU integrates the strengths of both parties, enhancing collaboration in biotechnology and drug development, with a particular focus on vascular disease, organ protection, and anti-aging. Through early validation of new functions for specific targets, patent applications, and AI drug screening, both parties are committed to addressing unmet clinical needs and improving the efficiency of new drug development.
From Industry-Academia "Collaboration" to "Co-Creation": Pioneering a New Chapter in the Biomedical Industry
Unlike typical industry-academia collaborations, what we aim for is industry-academia "co-creation." President Chi-Hung Lin of NYCU said: Co-creation means that the ecosystems of industry and academia today are vastly different from the past. At this time, both sides should find a topic of mutual interest and invest resources, ideas, and different mechanisms into this new topic, calling it 'co-creation.' The outcomes of co-creation can be a new industry, a new method, a new mechanism, or even a new economic model.
President Chi-Hung Lin believes that the development of "industry-academia co-creation" is already well-established in the semiconductor industry and AI field. However, in the biomedical field, it is merely at its inception. The signing of the MOU with TSH Biopharm can be considered a starting point for this "co-creation." President Lin stated that this collaboration will help students explore the biotech and pharmaceutical industry, medical environment, and socio-economic development. Through cross-disciplinary learning and practice, students can think about their future career directions, fostering the next generation of talents who possess both scientific and humanistic qualities.
This collaboration marks a significant milestone in Taiwan's industry-academia research and development. Through the joint efforts of both parties, it is hoped that more innovative drugs meeting the needs of Taiwanese patients can be developed, injecting new vitality into Taiwan's healthcare industry and driving the growth of the local biotech and pharmaceutical sectors.